HEL · ORNBV.HE
Orion Oyj
€100.00+€1.60 (+1.63%)
Orion Oyj’s quoted price sits in the upper half of its reported 52-week range, 0.5% below the high.
Loading market information…
HEL · HRTIS.HE · EUR
Stock price, earnings
Quote as of Oct 30, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Herantis Pharma Oyj’s quoted price sits in the lower half of its reported 52-week range, 58.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Herantis Pharma Oyj’s next earnings report is currently expected on Mar 4, 2027, with estimated earnings per share of -€0.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Herantis Pharma Oyj’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Herantis Pharma Oyj, a biotechnology company founded in Espoo, Finland, in 2008, is dedicated to developing innovative, disease-modifying CDNF-based treatments for Parkinson's disease (PD). Its pipeline features two key assets: HER-096, an advanced small, synthetic chemical peptidomimetic (a modified version of the active CDNF parent molecule) which is in preclinical stages as an xCDNF candidate for Parkinson's and other neurodegenerative conditions; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical trials for patients with PD.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:02 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -€0.05 |
| €0.00 |
| Q4 2022 | Mar 2, 2023 | -€0.11 | €0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€100.00+€1.60 (+1.63%)
Orion Oyj’s quoted price sits in the upper half of its reported 52-week range, 0.5% below the high.
€6.04+€0.03 (+0.5%)
Terveystalo Oyj’s quoted price sits in the lower half of its reported 52-week range, 42.03% below the high.
€10.38-€0.02 (-0.19%)
Revenio Group Oyj’s quoted price sits in the lower half of its reported 52-week range, 58.15% below the high.
€8.80-€0.07 (-0.79%)
Nexstim Plc’s quoted price sits in the lower half of its reported 52-week range, 42.67% below the high.
€0.80+€0.15 (+22.48%)
Nanoform Finland Oyj’s quoted price sits in the lower half of its reported 52-week range, 34.98% below the high.
€1.01-€0.01 (-0.99%)
Modulight Oyj’s quoted price sits in the lower half of its reported 52-week range, 27.17% below the high.
€2.11-€0.04 (-1.86%)
Biohit Oyj’s quoted price sits in the lower half of its reported 52-week range, 44.18% below the high.
€1.41+€0.04 (+3.07%)
Optomed Oyj’s quoted price sits in the lower half of its reported 52-week range, 67.44% below the high.
